Cavion

Cavion, a clinical-stage pharmaceutical company, focuses on developing treatments for cancer and neurological disorders by selectively inhibiting the T-type calcium channel (Cav3). Founded in 2003, it has made strides in pioneering therapies that engage Cav3 for solid tumor treatment. The company is currently undergoing Phase 1 safety and dose-finding clinical trials for brain cancer, with the goal of enhancing the effectiveness of combined chemotherapy, radiation, and targeted therapies for all solid tumors. Cavion's neurology program aims to introduce non-addictive, non-opioid T-type calcium channel antagonists for patients suffering from neuropathic pain and is also developing therapies for other neurological diseases like essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. The company's last investment was a $26.10M Series A investment at 06 January 2017, with participation from Novartis Venture Fund, Lilly Ventures, and Enso Ventures. Cavion's focus on pioneering ion channel inhibition for cancer and neurological diseases, along with its promising preclinical studies and ongoing clinical trials, positions it as a potential disruptor in the biotechnology, healthcare, and pharmaceutical industries.